Nanjing Damei Biopharmaceutical

Nanjing Damei Biopharmaceutical is a clinical-stage biotechnology company headquartered in Nanjing, China, dedicated to the discovery and development of novel protein degradation therapeutics. The company leverages its proprietary PROTAC (Proteolysis Targeting Chimera) platform to design small molecules that recruit the body's natural protein disposal system to eliminate disease-causing proteins. Its primary focus is on oncology, with a pipeline led by DM-001, a BTK degrader aimed at treating B-cell malignancies that have become resistant to traditional inhibitors. Damei Biopharma is also advancing programs targeting ALK and other key oncogenic drivers in solid tumors. The company's mission is to provide transformative treatments for patients with refractory cancers through its targeted protein degradation approach. Supported by prominent venture capital firms, the company operates within the Nanjing Jiangbei New Area biotech cluster.